End of stabilization period

Orphazyme A/S
Company announcement                                                                                       
No. 69/2020                                                                                                          
Company Registration No. 32266355
Copenhagen, Denmark, November 3, 2020 – With reference to company announcement no. 56/2020 dated September 29, 2020 regarding beginning of the stabilization period following the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the “ADSs”), each such ADS representing one ordinary share of Orphazyme, in the United States (the “U.S. Offering”), and a concurrent private placement of ordinary shares in Europe traded on Nasdaq Copenhagen A/S under the symbol “ORPHA” (the “European Private Placement”), Orphazyme A/S (“Orphazyme”) has received notification that BofA Securities, Inc., who is acting as stabilizing manager in the Global Offering, that the stabilization period has ended and that (i) stabilization measures have been taken between September 29, 2020 and October 28, 2020 as set out in the attached end of stabilization notification from BofA Securities, Inc., given on its and its affiliate, BofA Securities Europe SA, behalf to Orphazyme, with respect to the ADSs admitted to trading on the Nasdaq Global Select Market in the United States under the symbol “ORPH”; (ii) no stabilization transactions have been taken in the ordinary shares of Orphazyme admitted to trading on Nasdaq Copenhagen A/S during the stabilization period; and (iii) the stabilization measures with respect to the ADSs set out in the attached mid-stabilization notification have been taken.This company announcement does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.BofA Securities, Inc., Cowen and Company, LLC and Guggenheim Securities, LLC acted as joint book-running managers for the offering referred to herein.
For additional information, please contactOrphazyme A/SAnders Vadsholt, CFO                                  +45 28 98 90 55
About Orphazyme A/S 
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of Heat-Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA). About arimoclomol 
Arimoclomol is an investigational drug candidate that amplifies the production of Heat-Shock Proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, crosses the blood-brain barrier, and has now been studied in seven phase 1, four phase 2 and one pivotal phase 2/3 trial. Arimoclomol is in clinical development for NPC, Gaucher Disease, sIBM, and ALS. Arimoclomol has received orphan drug designation (ODD) for NPC, sIBM, and ALS in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC, sIBM and ALS. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC.